SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
1-Year Return
18.59%
This Quarter Return
+19.44%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.38B
AUM Growth
+$6.07M
(+0.26%)
Cap. Flow
-$155M
Cap. Flow
% of AUM
-6.52%
Top 10 Holdings %
Top 10 Hldgs %
39.28%
Holding
113
New
41
Increased
19
Reduced
15
Closed
24
Top Buys
| 1 |
Nike
NKE
|
$58.3M |
| 2 |
Wynn Resorts
WYNN
|
$56.5M |
| 3 |
AT&T
T
|
$54.3M |
| 4 |
Biohaven
BHVN
|
$52.5M |
| 5 |
Colgate-Palmolive
CL
|
$50.8M |
Top Sells
| 1 |
Microsoft
MSFT
|
$89.1M |
| 2 |
Walt Disney
DIS
|
$87.4M |
| 3 |
Amazon
AMZN
|
$82.9M |
| 4 |
IQVIA
IQV
|
$72.7M |
| 5 |
Global Payments
GPN
|
$71.2M |
Sector Composition
| 1 | Healthcare | 46.26% |
| 2 | Consumer Discretionary | 16.29% |
| 3 | Industrials | 12.13% |
| 4 | Consumer Staples | 8.08% |
| 5 | Technology | 7.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
PepGen
PEPG
$41.7M
| $11.1M | 0.47% |
828,087
-352,897
| -30% | -$4.72M |
|
52
Alvotech
ALVO
$2.51B
| $10M | 0.42% |
1,000,000
| – | – |
|
53
KalVista Pharmaceuticals
KALV
$755M
| $7.25M | 0.3% |
1,072,302
-634,798
| -37% | -$4.29M |
|
54
InflaRx
IFRX
$108M
| $6.65M | 0.28% |
2,146,240
| – | – |
|
55
Ventyx Biosciences
VTYX
$182M
| $6.11M | 0.26% |
186,400
| – | – |
|
|
MREO
56
Mereo BioPharma
MREO
$270M
| $5.52M | 0.23% |
7,364,438
| – | – |
|
57
Johnson & Johnson
JNJ
$428B
| $5.17M | 0.22% |
+29,290
| New | +$5.17M |
|
58
BioNTech
BNTX
$24.6B
| $4.6M | 0.19% |
+30,600
| New | +$4.6M |
|
59
ATAI Life Sciences
ATAI
$945M
| $4.36M | 0.18% |
1,637,960
+412,459
| +34% | +$1.1M |
|
60
Elanco Animal Health
ELAN
$8.57B
| $4.33M | 0.18% |
+354,400
| New | +$4.33M |
|
|
AKLI
61
DELISTED
Akili, Inc. Common Stock
AKLI
| $4.06M | 0.17% |
3,624,163
| – | – |
|
|
MOLN
62
Molecular Partners
MOLN
$144M
| $2.62M | 0.11% |
400,000
| – | – |
|
63
Galapagos
GLPG
$2.04B
| $2.09M | 0.09% |
+47,200
| New | +$2.09M |
|
64
Natera
NTRA
$23B
| $2.08M | 0.09% |
+51,900
| New | +$2.08M |
|
65
Danaher
DHR
$141B
| $1.97M | 0.08% |
8,383
-246,705
| -97% | -$58.1M |
|
66
Thermo Fisher Scientific
TMO
$183B
| $1.85M | 0.08% |
3,360
-111,365
| -97% | -$61.3M |
|
67
Spyre Therapeutics
SYRE
$1.03B
| $1.83M | 0.08% |
162,396
| – | – |
|
68
Abbott
ABT
$232B
| $1.13M | 0.05% |
+10,310
| New | +$1.13M |
|
69
Sanofi
SNY
$111B
| $1.1M | 0.05% |
+22,610
| New | +$1.1M |
|
70
AstraZeneca
AZN
$253B
| $1.06M | 0.04% |
+15,690
| New | +$1.06M |
|
71
Medtronic
MDT
$120B
| $728K | 0.03% |
+9,366
| New | +$728K |
|
72
Boston Scientific
BSX
$160B
| $654K | 0.03% |
+14,141
| New | +$654K |
|
|
73
IQVIA
IQV
$31B
| $606K | 0.03% |
2,959
-354,726
| -99% | -$72.7M |
|
74
argenx
ARGX
$44.7B
| $576K | 0.02% |
+1,520
| New | +$576K |
|
75
Illumina
ILMN
$15.2B
| $568K | 0.02% |
+2,889
| New | +$568K |
|